Aurion Biotech

Aurion Biotech, headquartered in Seattle and Boston, is a clinical-stage biotechnology company. The company's mission is to cure blindness and transform the lives of millions of patients by developing a differentiated platform for advanced therapies to treat ocular diseases. Aurion Biotech's first candidate program is a cell therapy for the treatment of corneal endothelial disease, a condition that affects millions of people worldwide and includes symptoms such as blurred vision, glare, discomfort, and pain.